Dupixent's 2020 Revenue Figures
Dupixent (dupilumab), developed by Sanofi and Regeneron, generated $3.57 billion in global net sales in 2020, up from $1.98 billion in 2019.[1]
Exact Revenue Growth Amount
The absolute revenue growth was $1.59 billion ($3.57B - $1.98B).[1]
Growth Rate
This represented an 80% year-over-year increase.[1][2]
What Drove the Growth
Sales surged due to expanded U.S. and EU approvals for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. U.S. revenue alone hit $2.6 billion, boosted by strong demand and label expansions.[1][2]
Comparison to Prior Years
| Year | Revenue ($B) | YoY Growth (%) |
|------|--------------|----------------|
| 2019 | 1.98 | 132 |
| 2020 | 3.57 | 80 |
| 2021 | 5.56 | 56 |[1][2]
Patent and Exclusivity Timeline
Core U.S. patents for Dupixent extend to 2031, with potential pediatric exclusivity pushing to 2032. No biosimilars are approved yet; challenges from Almirall and others are ongoing.[3]
[1]: Sanofi 2020 Annual Report
[2]: Regeneron 2020 Annual Report
[3]: DrugPatentWatch.com - Dupixent Patents